After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

Given the absence of an effective vaccine for protection against HIV-1 infection, passive
immunization strategies that utilize potent broadly neutralizing antibodies (bnAbs) to block …

Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …

Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been
induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare …

The SARS-CoV-2 pandemic has unprecedented implications for public health, social life,
and the world economy. Because approved drugs and vaccines are limited or not available …

The human immune response must continuously adapt to newly emerging SARS-CoV-2
variants. To investigate how B cells respond to repeated SARS-CoV-2 antigen exposure by …

Understanding the specificities of human serum antibodies that broadly neutralize HIV can
inform prevention and treatment strategies. Here, we describe a deep mutational scanning …

Abstract HIV-1 envelope (Env) exhibits distinct conformational changes in response to host
receptor (CD4) engagement. Env, a trimer of gp120 and gp41 heterodimers, has been …

Since their discovery, antibodies capable of broad neutralisation have been at the forefront
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …

As exemplified by the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) pandemic, there is a strong demand for rapid high-throughput isolation pipelines to …